KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc.

Biotechnology: Pharmaceutical Preparations

Health Care

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which has completed Phase II clinical trial for an oral on-demand therapy for acute HAE attacks; and KVD824, an oral product candidate for the treatment of HAE. The company is headquartered in Cambridge, Massachusetts.

IPO Year: 2015

Exchange: NASDAQ

Website: kalvista.com

Peers

$BCRX

$VRNA

Recent Analyst Ratings for KalVista Pharmaceuticals Inc.

Date	Price Target	Rating	Analyst
1/31/2025	$19.00	Mkt Outperform	JMP Securities
1/7/2025	$30.00	Buy	TD Cowen
12/18/2024	$22.00	Buy	BofA Securities
3/11/2022	$48.00 → $42.00	Buy	Needham
12/10/2021	$50.00 → $48.00	Buy	Needham

See more ratings

KalVista Pharmaceuticals Inc.

Peers

Recent Analyst Ratings for KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CHIEF EXECUTIVE OFFICER Palleiko Benjamin L converted options into 15,625 shares and sold $103,950 worth of shares (7,169 units at $14.50), increasing direct ownership by 3% to 315,074 units (SEC Form 4)

CHIEF MEDICAL OFFICER Audhya Paul K. converted options into 5,000 shares and sold $24,272 worth of shares (2,146 units at $11.31), increasing direct ownership by 3% to 113,026 units (SEC Form 4)

CHIEF DEVELOPMENT OFFICER Yea Christopher sold $21,782 worth of shares (1,926 units at $11.31) and converted options into 3,125 shares, increasing direct ownership by 1% to 98,189 units (SEC Form 4)

CHIEF MEDICAL OFFICER Audhya Paul K. sold $31,933 worth of shares (2,689 units at $11.88) and converted options into 6,250 shares, increasing direct ownership by 3% to 110,172 units (SEC Form 4)

CHIEF DEVELOPMENT OFFICER Yea Christopher converted options into 3,750 shares and sold $27,516 worth of shares (2,317 units at $11.88), increasing direct ownership by 1% to 96,990 units (SEC Form 4)

CHIEF EXECUTIVE OFFICER Palleiko Benjamin L converted options into 23,250 shares and sold $118,743 worth of shares (9,999 units at $11.88), increasing direct ownership by 5% to 306,618 units (SEC Form 4)

CHIEF DEVELOPMENT OFFICER Yea Christopher converted options into 4,205 shares and sold $30,791 worth of shares (2,600 units at $11.84), increasing direct ownership by 2% to 95,557 units (SEC Form 4)

CHIEF EXECUTIVE OFFICER Palleiko Benjamin L converted options into 9,364 shares and sold $45,097 worth of shares (3,808 units at $11.84), increasing direct ownership by 2% to 293,367 units (SEC Form 4)

CHIEF MEDICAL OFFICER Audhya Paul K. converted options into 6,447 shares and sold $32,876 worth of shares (2,776 units at $11.84), increasing direct ownership by 4% to 106,611 units (SEC Form 4)

Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $235,500 worth of shares (25,000 units at $9.42) (SEC Form 4)

KalVista Pharmaceuticals Inc. SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by KalVista Pharmaceuticals Inc.

SEC Form 8-K filed by KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure

SEC Form 8-K filed by KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by KalVista Pharmaceuticals Inc.

SEC Form S-8 filed by KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure

KalVista Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by KalVista Pharmaceuticals Inc.